Efficacy and safety of a 4 year combination therapy of growth hormone and gonadotropin- releasing hormone agonist in children with a short predicted height.
Status: Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 02 Dec 2017
Price : $35 *
At a glance
- Drugs Somatrogon (Primary) ; Triptorelin (Primary)
- Indications Short stature
- Focus Therapeutic Use
- 23 Aug 2017 Planned End Date changed from 1 Apr 2017 to 1 Apr 2023.
- 23 Aug 2017 Planned primary completion date changed from 1 Jan 2017 to 1 Jan 2023.
- 23 Aug 2017 Status changed from recruiting to active, no longer recruiting.